By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login

Lexeo Therapeutics, Inc. Common Stock (LXEO)

NASDAQ Currency in USD
$5.18
-$0.02
-0.38%
Last Update: 11 Sept 2025, 20:00
$171.96M
Market Cap
-1.57
P/E Ratio (TTM)
Forward Dividend Yield
$1.45 - $11.72
52 Week Range

LXEO Stock Price Chart

Explore Lexeo Therapeutics, Inc. Common Stock interactive price chart. Choose custom timeframes to analyze LXEO price movements and trends.

LXEO Company Profile

Discover essential business fundamentals and corporate details for Lexeo Therapeutics, Inc. Common Stock (LXEO) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

3 Nov 2023

Employees

75.00

CEO

R. Nolan Townsend

Description

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

LXEO Financial Timeline

Browse a chronological timeline of Lexeo Therapeutics, Inc. Common Stock corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 12 Nov 2025

EPS estimate is -$0.51.

Earnings released on 14 Aug 2025

EPS came in at -$0.60 surpassing the estimated -$0.64 by +6.25%.

Earnings released on 12 May 2025

EPS came in at -$0.99 falling short of the estimated -$0.80 by -23.75%.

Earnings released on 24 Mar 2025

EPS came in at -$0.78 surpassing the estimated -$0.87 by +10.34%.

Earnings released on 13 Nov 2024

EPS came in at -$0.89 falling short of the estimated -$0.65 by -36.92%.

Earnings released on 12 Aug 2024

EPS came in at -$0.64 surpassing the estimated -$0.69 by +7.25%.

Earnings released on 9 May 2024

EPS came in at -$0.77 falling short of the estimated -$0.76 by -1.32%.

Earnings released on 11 Mar 2024

EPS came in at -$0.85 falling short of the estimated -$0.73 by -16.44%.

Earnings released on 6 Nov 2023

EPS came in at -$12.36 falling short of the estimated -$2.60 by -375.38%.

Earnings released on 30 Jun 2023

EPS came in at -$0.53 .

Earnings released on 31 Mar 2023

EPS came in at -$0.74 .

Earnings released on 31 Dec 2022

EPS came in at -$0.59 , while revenue for the quarter reached $654.00K .

Earnings released on 30 Sept 2022

EPS came in at -$0.68 , while revenue for the quarter reached $531.00K .

Earnings released on 30 Jun 2022

EPS came in at -$0.60 , while revenue for the quarter reached $37.00K .

Earnings released on 30 Mar 2022

EPS came in at -$0.47 , while revenue for the quarter reached $85.55K .

LXEO Stock Performance

Access detailed LXEO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run